Douglas Hornick, MD
Pulmonary Disease · Iowa City, IANPI 1437147386
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,400 of the $8,149 with a category attached, or 78.5%. Insmed, Inc. accounts for 95.1% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2019 at $7,745 and has fallen 98.3% since, to $130 in 2024.
Across 11 payments — averaging $740.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$8K
- Mannkind Corporation$403
Across 296 payments — averaging $1874.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mannkind Corporation$319K
- Insmed, Inc.$159K
- Paratek Pharmaceuticals, Inc.$40K
- Vertex$21K
- Verona Pharma, Inc.$11K
- Boehringer Ingelheim International GmbH$3K
- plus $1K from 1 others
What the payments were for
- Consulting fees$6,40079%
- Travel & lodging$1,22415%
- Food & beverage$5246%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 8 | $7,745 |
| Mannkind Corporation | 3 | $403 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,149 in reported general payments places this provider in the 75th percentile of 110 pulmonary disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 44 | $1,124,860 |
| NuzyraOmadacycline Tosylate | 12 | $185,479 |
| CaystonAztreonam Lysine | 11 | $133,420 |
| CreonLipase/Protease/Amylase | 22 | $94,283 |
| Dupixent PenDupilumab | 22 | $76,879 |
| TezspireTezepelumab-Ekko | 16 | $66,673 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 70 | $35,733 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $22,587 |
| ColistimethateColistin (Colistimethate Na) | 31 | $17,131 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $13,589 |
| DuleraMometasone/Formoterol | 26 | $9,190 |
| Spiriva HandihalerTiotropium Bromide | 17 | $9,170 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $8,850 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $7,329 |
| Azithromycin | 368 | $6,604 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Iowa City
- Alejandro ComellasIowa City$54K
- Rolando Sanchez SanchezIowa City$12K
- Nabeel HamzehIowa City$9K
- Robert SmythIowa City$6K
- Joel KlineIowa City$5K
- Tahuanty PenaIowa City$2K
- Alan MoyIowa City$2K
- Kimberly Baker-El AbiadIowa City$831
- Bryan KrajicekCouncil Bluffs$470K
- Sumit MukherjeeCouncil Bluffs$264K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.